Baird Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $82
Optimistic Growth and Improved Financial Outlook for Bio-Techne: A Buy Recommendation
Scotiabank Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $83
Scotiabank Reaffirms Their Buy Rating on Bio-Techne (TECH)
Bio-Techne Analyst Ratings
Benchmark Co. Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $95
Benchmark Co. Remains a Buy on Bio-Techne (TECH)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Pediatrix Medical Group (MD) and Arcus Biosciences (RCUS)
Buy Rating Affirmed for Bio-Techne on Strong Consumables Foundation and Market Growth Potential
Citigroup Adjusts Price Target on Bio-Techne to $80 From $85
Bio-Techne Analyst Ratings
RBC Capital Keeps Their Hold Rating on Bio-Techne (TECH)
Citi Downgrades Bio-Techne to Neutral, Cites Valuation
Bio-Techne Analyst Ratings
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating
Benchmark Reiterates Buy on Bio-Techne, Maintains $95 Price Target
Analysts' Top Healthcare Picks: Bio-Techne (TECH), Gilead Sciences (GILD)
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept
Bio-Techne Analyst Ratings